Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)

NCT02795325 is registered in ClinicalTrials.gov with Dicerna Pharmaceuticals, Inc., a Novo Nordisk company as lead sponsor.

NCT NCT02795325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02795325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Phase
Phase 1
Overall status
Terminated
Start date
May 13, 2016
Completion date
October 14, 2016
Enrollment
41 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

primary hyperoxaluria type 1